(Total Views: 581)
Posted On: 12/27/2020 1:00:30 PM
Post# of 153984
“I wonder if knowledge of supply, and allowing Cytodyn to ramp up production before demand skyrockets,while still allowing more patients to have access to LL, played any part in the decision to finish out the study too.”
What exactly are you implying? That Leronlimab has demonstrated EUA level efficacy in the S/C trial but due to supply limitations, the trial was continued? If so, that’s very unlikely as CYDY would never do that. OWS is working with CYDY and will assist in production if/when EUA is given.
The bottom line is this: the final patient in the 28 day S/C trial will complete the 28 days on or around January 11th, 2021. Based on the time it took the release the M2M data, I’m assuming we’ll see a PR 2-3 weeks later. We will know then if leronlimab will receive an EUA.
What exactly are you implying? That Leronlimab has demonstrated EUA level efficacy in the S/C trial but due to supply limitations, the trial was continued? If so, that’s very unlikely as CYDY would never do that. OWS is working with CYDY and will assist in production if/when EUA is given.
The bottom line is this: the final patient in the 28 day S/C trial will complete the 28 days on or around January 11th, 2021. Based on the time it took the release the M2M data, I’m assuming we’ll see a PR 2-3 weeks later. We will know then if leronlimab will receive an EUA.
(2)
(0)
